GRTS Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 108086 min ago

@ $2.18

Ausgestellt: 14 Feb 2024 @ 20:06

Rendite: -62.94%

Vorheriges Signal: Feb 13 - 21:42

Vorheriges Signal: Verkaufen

Rendite: 3.82 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases...

Stats
Tagesvolumen	1.04M
Durchschnittsvolumen	2.90M
Marktkapitalisierung	85.77M
EPS	$0 ( 2024-03-14 )
Nächstes Ertragsdatum	( $-0.300 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.670
ATR14	$0.00100 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-01	Hawryluk Matthew	Buy	35 000	Common Stock
2024-02-01	Hawryluk Matthew	Buy	180 000	Stock Option (Right to Buy)
2024-02-01	Jones Erin	Buy	40 000	Common Stock
2024-02-01	Jones Erin	Buy	235 000	Stock Option (Right to Buy)
2024-02-01	Economides Vassiliki	Buy	35 000	Common Stock

INSIDER POWER
100.00
Last 97 transactions
Buy: 5 929 842 \| Sell: 139 571

Volumen Korrelation

Lang: -0.03 (neutral)

Kurz: -0.56 (weak negative)

Signal:(29.634) Neutral

Gritstone Oncology Inc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Gritstone Oncology Inc Korrelation - Währung/Rohstoff

0.00
( neutral )

0.17
( neutral )

0.00
( neutral )

-0.76
( moderate negative )

0.01
( neutral )

Gritstone Oncology Inc Finanzdaten

Annual	2023
Umsatz:	$1.33M
Bruttogewinn:	$-6.26M (-470.32 %)
EPS:	$-1.200

FY	2023
Umsatz:	$1.33M
Bruttogewinn:	$-6.26M (-470.32 %)
EPS:	$-1.200

FY	2022
Umsatz:	$9.27M
Bruttogewinn:	$-6.42M (-69.28 %)
EPS:	$-1.240

FY	2021
Umsatz:	$48.21M
Bruttogewinn:	$48.21M (100.00 %)
EPS:	$-0.965

Financial Reports:

No articles found.

Gritstone Oncology Inc

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.